Take advantage of the currently offered discount on annual memberships and give CIP a try. The offer comes with a 11 month money guarantee , for first time members.Conservative Income Portfolio targets the best value stocks with the highest margins of safety. The volatility of these investments is further lowered using the best priced options. Our Enhanced Equity Income Solutions Portfolio is designed to reduce volatility while generating 7-9% yields.Over the last four years that we have covered Viatris Inc ...

Viatris reported mixed results for Q4 2024, missing revenue and EPS expectations, despite noteworthy debt reduction and portfolio adjustments.Viatris (VTRS -15.61%), a global healthcare company known for its broad portfolio of pharmaceutical products, released its fourth-quarter 2024 results on Feb. 27. Despite achieving substantial debt reduction and strategic advancements, Viatris fell short of analysts' forecasts. The adjusted earnings per share (EPS) stood at $0.54, missing the estimated $0.56, while to ...

Core Viewpoint - Viatris reported quarterly earnings of $0.54 per share, missing the Zacks Consensus Estimate of $0.57 per share, and showing a decline from $0.61 per share a year ago, indicating an earnings surprise of -5.26% [1][2] Financial Performance - The company posted revenues of $3.53 billion for the quarter ended December 2024, missing the Zacks Consensus Estimate by 2.04%, and down from $3.84 billion year-over-year [2] - Over the last four quarters, Viatris has surpassed consensus EPS estimates two times and topped revenue estimates just once [2] Stock Performance - Viatris shares have declined approximately 9.7% since the beginning of the year, contrasting with the S&P 500's gain of 1.3% [3] - The current Zacks Rank for Viatris is 4 (Sell), indicating expected underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.63 on revenues of $3.58 billion, and for the current fiscal year, it is $2.57 on revenues of $14.25 billion [7] - The trend for estimate revisions ahead of the earnings release was unfavorable, which may impact future stock movements [6] Industry Context - The Medical Services industry, to which Viatris belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Q4 & Full Year 2024 Earnings February 27, 2025 1 This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited. © 2025 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. Forward Looking Statements This presentation contains "forward-looking statements". These statements are made pursuant to the safe harbor provisions of the Private Securities Litiga ...

Financial Performance - Viatris reported total revenues of $14.7 billion for 2024, a decline of 5% compared to 2023, with operational revenue growth of 2% when excluding divestitures[3]. - U.S. GAAP net loss for 2024 was $(634) million, with adjusted EPS of $2.65 per share, a decrease of 10% from 2023[3]. - Total net sales in developed markets declined by 3%, while emerging markets saw a decline of 12% in 2024[5]. - Fourth quarter 2024 total net sales were $3.5 billion, up 1% on a divestiture-adjusted operational basis compared to fourth-quarter 2023 results[14]. - Total revenues for the year ended December 31, 2024, were $14,739.3 million, down from $15,426.9 million in 2023[36]. - The company reported a net loss of $516.5 million for Q4 2024, compared to a net loss of $765.6 million in Q4 2023[36]. - Adjusted EBITDA for the year ended December 31, 2024, was $4,669.4 million, down from $5,124.1 million in 2023, reflecting a decrease of 8.9%[46]. - Total revenue from key global products for the year ended December 31, 2024, was $1,468.8 million, a decrease of 5.8% from $1,559.3 million in 2023[41]. Cash Flow and Debt Management - The company achieved new product revenues of $582 million in 2024 and free cash flow of $2.0 billion, exceeding its guidance[2]. - U.S. GAAP net cash provided by operating activities was $483 million in the fourth quarter and $2.3 billion for the year, with free cash flow of $685 million in the fourth quarter and $2.6 billion for the year[14]. - Viatris ended 2024 with a gross leverage ratio of 2.9x after repaying $3.7 billion of debt[2]. - The company paid down approximately $1.4 billion in debt during the fourth quarter, achieving a long-term gross leverage target of 2.9x[14]. - Total reported debt as of December 31, 2024, was $14,039.5 million, with a gross debt to adjusted EBITDA ratio of 2.9x[55]. - Long-term debt decreased from $16,188.1 million in 2023 to $14,038.9 million in 2024[39]. Future Guidance and Expectations - Financial guidance for 2025 includes total revenues estimated between $13.5 billion and $14 billion, with a midpoint of $13.75 billion[18]. - Adjusted EBITDA for 2025 is projected to be between $3.9 billion and $4.2 billion, with a midpoint of $4.05 billion[18]. - Adjusted EPS for 2025 is expected to range from $2.12 to $2.26, with a midpoint of $2.19[18]. - The company expects to deliver $450 million to $550 million in new product revenues in 2025[31]. - The company expects U.S. GAAP net cash provided by operating activities for 2025 to be between $2.2 billion and $2.5 billion, with a midpoint of approximately $2.35 billion[17]. Operational Challenges - The company expects a negative impact of approximately $500 million on total revenues and $385 million on adjusted EBITDA in 2025 due to the FDA warning letter and import alert related to its Indore facility[11]. - The anticipated negative impact from the Indore facility is approximately $500 million to total revenues and $385 million to adjusted EBITDA[17]. - Viatris is implementing a comprehensive remediation plan for its Indore facility, with expectations for completion in a few months[12]. - The company has implemented a comprehensive remediation plan following an FDA inspection, with efforts more than halfway completed[31]. Research and Development - The company anticipates six Phase 3 data readouts and important late-stage development milestones for selatogrel, cenerimod, and sotagliflozin in 2025[3]. - Research and development expenses included $2.8 million in special items for the year ended December 31, 2024[46]. - Research and development (R&D) expenses for the three months ended December 31, 2024, were $206.5 million, representing 6% of total revenues, compared to 5% in the same period of 2023[50]. Shareholder Returns - Viatris plans to return $500 million to $650 million in capital to shareholders through share repurchases in 2025[3]. - The company plans to prioritize capital return in 2025, including $500 million to $650 million in share repurchases[30]. Miscellaneous - The company recorded a goodwill impairment charge of $321.0 million for the year ended December 31, 2024, related to the JANZ reporting unit[45]. - The company incurred acquisition and divestiture-related costs of $361.0 million for the year ended December 31, 2024[44]. - Adjusted earnings from operations for the three months ended December 31, 2024, were $870.6 million, down from $986.6 million in 2023[51].

Core Viewpoint - Viatris Inc. has announced a 2025 dividend policy of $0.48 per share, with a quarterly dividend of $0.12, marking the fifth consecutive year of dividend payments [1]. Company Overview - Viatris Inc. is a global healthcare company that combines generics and brand medications to address healthcare needs worldwide, supplying high-quality medicines to approximately 1 billion patients annually [2]. - The company aims to empower individuals to live healthier lives at every stage, with a diverse portfolio and a unique global supply chain [2]. - Viatris is headquartered in the U.S. and has global centers in Pittsburgh, Shanghai, and Hyderabad, India [2].

Core Viewpoint - Analysts forecast that Viatris (VTRS) will report quarterly earnings of $0.57 per share, reflecting a year-over-year decline of 6.6%, with anticipated revenues of $3.6 billion, down 6.3% compared to the previous year [1]. Earnings Projections - The consensus EPS estimate for the quarter has not changed over the past 30 days, indicating that analysts have not revised their initial projections [2]. - Revisions to earnings projections are crucial for predicting investor behavior, as empirical studies show a strong correlation between earnings estimate trends and short-term stock performance [3]. Revenue Estimates - Analysts predict 'Total Net Sales' to be $3.59 billion, indicating a year-over-year decline of 6.2% [5]. - 'Other revenues' are expected to reach $11.47 million, showing a slight increase of 0.6% year-over-year [5]. - 'Net Sales- JANZ' is forecasted at $366.35 million, reflecting a decrease of 1.6% from the prior year [5]. Market Segment Analysis - 'Net Sales- Emerging Markets' is projected to be $538.93 million, down 13% year-over-year [6]. - 'Net Sales- Developed Markets- Brands' is estimated at $1.21 billion, indicating a decline of 7.7% [6]. - 'Net Sales- JANZ- Brands' is expected to be $198.33 million, down 0.6% from the previous year [6]. Additional Segment Insights - 'Net Sales- JANZ- Generics' is anticipated to reach $168.03 million, reflecting a year-over-year decline of 13.1% [7]. - 'Net Sales- Emerging Markets- Brands' is projected at $401.94 million, showing an increase of 7.3% [7]. - 'Net Sales- Emerging Markets- Generics' is expected to be $171.99 million, indicating a significant decline of 29.7% [7]. Regional Sales Forecast - 'Net Sales- Greater China' is forecasted to be $553.04 million, reflecting a year-over-year increase of 7.3% [8]. - 'Net Sales- Developed Markets' is expected to reach $2.17 billion, indicating a decline of 6.5% [8]. - 'Net Sales- Developed Markets- Generics' is projected at $1.06 billion, reflecting a significant decrease of 26.1% from the prior year [8]. Stock Performance - Shares of Viatris have changed by +0.5% in the past month, contrasting with a -0.5% move in the Zacks S&P 500 composite [9]. - With a Zacks Rank 4 (Sell), VTRS is expected to underperform the overall market in the near future [10].

Core Viewpoint - Viatris (VTRS) is set to report its fourth-quarter and full-year 2024 results on February 27, 2025, with revenue estimates at $3.60 billion and earnings at $0.57 per share [1]. Revenue Segments - Viatris reports financial results across five segments: Developed Markets, Emerging Markets, Japan, Australia and New Zealand (JANZ), and Greater China [2]. - Developed Markets are expected to contribute $2.2 billion in revenue, driven by new product performance and strong generics [3]. - Emerging Markets are projected to generate $539 million, supported by the expansion of the cardiovascular portfolio in Latin America [4]. - JANZ markets are estimated to bring in $366 million, fueled by new product launches in Australia and volume growth in Japan [4]. - Greater China is anticipated to yield $553 million, benefiting from strong demand across various channels [5]. Product Categories - The brand business constitutes the majority of Viatris' portfolio, with performance bolstered by the cardiovascular portfolio expansion and strong growth in Europe and Greater China [6]. - Generic growth is attributed to the strength in the European portfolio and complex products in North America [6]. Operating Expenses - Operating expenses are likely to have increased due to investments in SG&A for the eye care franchise, new product launches, and advancements in key R&D programs [7]. Share Price Performance - Viatris' shares have decreased by 13.2% over the past year, compared to a 15.8% decline in the industry [8]. Earnings Surprise History - The company has a mixed earnings surprise history, beating estimates in two of the last four quarters and missing in the other two, with an average surprise of 0.33% [10]. Earnings Prediction Model - The current model does not predict a definitive earnings beat for Viatris, as it has an Earnings ESP of -3.51% and a Zacks Rank of 4 (Sell) [11][12].

Core Viewpoint - Viatris (VTRS) is anticipated to report a year-over-year decline in earnings due to lower revenues, which could significantly influence its near-term stock price depending on how actual results compare to consensus estimates [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for February 27, 2025, with a consensus estimate of $0.57 per share, reflecting a year-over-year decrease of 6.6%. Revenues are projected to be $3.6 billion, down 6.3% from the previous year [3][2]. - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Viatris is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -3.51%, indicating a bearish sentiment among analysts [10]. - The stock currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat [11]. Historical Performance - In the last reported quarter, Viatris exceeded the expected earnings of $0.68 per share by delivering $0.75, resulting in a surprise of +10.29%. Over the past four quarters, the company has beaten consensus EPS estimates twice [12][13]. Conclusion - Viatris does not appear to be a strong candidate for an earnings beat based on current estimates and rankings, suggesting that investors should consider additional factors before making investment decisions [16].

Core Insights - Viatris Inc. will report its financial results for Q4 and the full year 2024 on February 27, 2025, with a webcast scheduled for 8:30 a.m. ET to discuss the results [1] - The company aims to provide access to high-quality medicines to approximately 1 billion patients globally each year, addressing healthcare needs across various life stages and conditions [2] Company Overview - Viatris is a global healthcare company that combines generics and brand-name products to meet healthcare needs [2] - The company is headquartered in the U.S. and has global centers in Pittsburgh, Shanghai, and Hyderabad, India [2] - Viatris has a diverse portfolio of medicines and a unique global supply chain designed to enhance access to healthcare [2]